mTOR signaling pathway genes in focal epilepsies

Progress in Brain Research

Volumn 226, Issue , 2016, Pages 61-79

  Baulac, S ^a,b,c,d,e  

^a SORBONNE UNIVERSITÉ   (France)

^b INSERM   (France)

^c CNRS   (France)

^d INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

DEPDC5; GATOR1; Genetics; mTOR; NPRL2; NPRL3; SUDEP

Indexed keywords

DISHEVELLED PROTEIN; EGL 10 PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; NITROGEN PERMEASE REGULATOR LIKE 2 PROTEIN; NITROGEN PERMEASE REGULATOR LIKE 3 PROTEIN; PERMEASE; PLECKSTRIN; PROTEIN; TARGET OF RAPAMYCIN KINASE; UNCLASSIFIED DRUG; DEPDC5 PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; NPRL2 PROTEIN, HUMAN; NPRL3 PROTEIN, HUMAN; REPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

BRAIN SURGERY; BRAIN TISSUE; CLINICAL FEATURE; CORTICAL DYSPLASIA; FAMILY; FOCAL EPILEPSY; GENE; GENE MUTATION; GENETICS; HUMAN; IN VITRO STUDY; MOLECULAR PATHOLOGY; NEUROBIOLOGY; NONHUMAN; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SOMATIC MUTATION; ANIMAL; GENETIC PREDISPOSITION; METABOLISM; MUTATION; PHYSIOLOGY;

ANIMALS; EPILEPSIES, PARTIAL; GENETIC PREDISPOSITION TO DISEASE; GTPASE-ACTIVATING PROTEINS; HUMANS; MUTATION; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 85007543171     PISSN: 00796123     EISSN: 18757855     Source Type: Book Series    
DOI: 10.1016/bs.pbr.2016.04.013     Document Type: Chapter

References (41)

1. Algret, R., et al. Molecular architecture and function of the SEA complex, a modulator of the TORC1 pathway. Mol. Cell. Proteomics 13 (2014), 2855–2870.
2. Bagnall, R.D., et al. Exome-based analysis of cardiac arrhythmia, respiratory control, and epilepsy genes in sudden unexpected death in epilepsy. Ann. Neurol. 79 (2016), 522–534.
3. Bar-Peled, L., et al. A tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science 340 (2013), 1100–1106.
4. Baulac, S., Genetics advances in autosomal dominant focal epilepsies: focus on DEPDC5. Prog. Brain Res. 213 (2014), 123–139.
5. Baulac, S., et al. Familial focal epilepsy with focal cortical dysplasia due to DEPDC5 mutations. Ann. Neurol. 77 (2015), 675–683.
6. Baybis, M., et al. mTOR cascade activation distinguishes tubers from focal cortical dysplasia. Ann. Neurol. 56 (2004), 478–487.
7. Blumcke, I., et al. The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc task force of the ILAE diagnostic methods commission. Epilepsia 52 (2011), 158–174.
8. Carvill, G.L., et al. Epileptic spasms are a feature of DEPDC5 mTORopathy. Neurol. Genet., 1, 2015, e17.
9. Curatolo, P., Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy. Pediatr. Neurol. 52 (2015), 281–289.
10. D'Gama, A.M., et al. Mammalian target of rapamycin pathway mutations cause hemimegalencephaly and focal cortical dysplasia. Ann. Neurol. 77 (2015), 720–725.
11. Dibbens, L.M., et al. Mutations in DEPDC5 cause familial focal epilepsy with variable foci. Nat. Genet. 45 (2013), 546–551.
12. Dokudovskaya, S., Rout, M.P., SEA you later alli-GATOR—a dynamic regulator of the TORC1 stress response pathway. J. Cell Sci. 128 (2015), 2219–2228.
13. Dutchak, P.A., et al. Regulation of hematopoiesis and methionine homeostasis by mTORC1 inhibitor NPRL2. Cell Rep. 12 (2015), 371–379.
14. Insel, T.R., Brain somatic mutations: the dark matter of psychiatric genetics?. Mol. Psychiatry 19 (2014), 156–158.
15. Ishida, S., et al. Mutations of DEPDC5 cause autosomal dominant focal epilepsies. Nat. Genet. 45 (2013), 552–555.
16. Jamuar, S.S., et al. Somatic mutations in cerebral cortical malformations. N. Engl. J. Med. 371 (2014), 733–743.
17. Korenke, G.C., et al. Nocturnal frontal lobe epilepsy caused by a mutation in the GATOR1 complex gene NPRL3. Epilepsia 57 (2016), e60–e63.
18. Kowalczyk, M.S., et al. Nprl3 is required for normal development of the cardiovascular system. Mamm. Genome 23 (2012), 404–415.
19. Lal, D., et al. DEPDC5 mutations in genetic focal epilepsies of childhood. Ann. Neurol. 75 (2014), 788–792.
20. Laplante, M., Sabatini, D.M., mTOR signaling in growth control and disease. Cell 149 (2012), 274–293.
21. Lasarge, C.L., Danzer, S.C., Mechanisms regulating neuronal excitability and seizure development following mTOR pathway hyperactivation. Front. Mol. Neurosci., 7, 2014, 18.
22. Lim, K.C., Crino, P.B., Focal malformations of cortical development: new vistas for molecular pathogenesis. Neuroscience 252 (2013), 262–276.
23. Lim, J.S., et al. Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy. Nat. Med. 21 (2015), 395–400.
24. Marsan, E., et al. Depdc5 knockout rat: a novel model of mTORopathy. Neurobiol. Dis. 89 (2016), 180–189.
25. Martin, C., et al. A recurrent mutation in DEPDC5 predisposes to focal epilepsies in the French-Canadian population. Clin. Genet. 86 (2014), 570–574.
26. Miyata, H., et al. Insulin signaling pathways in cortical dysplasia and TSC-tubers: tissue microarray analysis. Ann. Neurol. 56 (2004), 510–519.
27. Nakashima, M., et al. Somatic mutations in the MTOR gene cause focal cortical dysplasia type IIb. Ann. Neurol. 78 (2015), 375–386.
28. Nascimento, F.A., et al. Two definite cases of sudden unexpected death in epilepsy in a family with a DEPDC5 mutation. Neurol. Genet., 1, 2015, e28.
29. Panchaud, N., et al. Amino acid deprivation inhibits TORC1 through a GTPase-activating protein complex for the rag family GTPase Gtr1. Sci. Signal., 6, 2013, ra42.
30. Picard, F., et al. DEPDC5 mutations in families presenting as autosomal dominant nocturnal frontal lobe epilepsy. Neurology 82 (2014), 2101–2106.
31. Pippucci, T., et al. Epilepsy with auditory features: a heterogeneous clinico-molecular disease. Neurol. Genet., 1, 2015, e5.
32. Poduri, A., et al. Somatic mutation, genomic variation, and neurological disease. Science, 341, 2013, 1237758.
33. Ricos, M.G., et al. Mutations in the mammalian target of rapamycin pathway regulators NPRL2 and NPRL3 cause focal epilepsy. Ann. Neurol. 79 (2016), 120–131.
34. Scerri, T., et al. Familial cortical dysplasia type IIA caused by a germline mutation in DEPDC5. Ann. Clin. Transl. Neurol. 2 (2015), 575–580.
35. Scheffer, I.E., et al. Mutations in mammalian target of rapamycin regulator DEPDC5 cause focal epilepsy with brain malformations. Ann. Neurol. 75 (2014), 782–787.
36. Sim, J.C., et al. Familial cortical dysplasia caused by mutation in the mammalian target of rapamycin regulator NPRL3. Ann. Neurol. 79 (2016), 132–137.
37. Sisodiya, S.M., et al. Focal cortical dysplasia type II: biological features and clinical perspectives. Lancet Neurol. 8 (2009), 830–843.
38. Striano, P., et al. DEPDC5 mutations are not a frequent cause of familial temporal lobe epilepsy. Epilepsia 56 (2015), e168–e171.
39. Surges, R., Sander, J.W., Sudden unexpected death in epilepsy: mechanisms, prevalence, and prevention. Curr. Opin. Neurol. 25 (2012), 201–207.
40. van Kranenburg, M., et al. Preliminary functional assessment and classification of DEPDC5 variants associated with focal epilepsy. Hum. Mutat. 36 (2015), 200–209.
41. Weckhuysen, S., et al. Involvement of GATOR complex genes in familial focal epilepsies and focal cortical dysplasia. Epilepsia, 2016, 10.1111/epi.13391.